Related Experiment Videos
Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors
1Virginia Commonwealth University, Medical College of Virginia, Richmond 23298-0533, USA.
Summary
Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, like statins, can dangerously interact with other drugs, foods, and diseases. Understanding these interactions is crucial for patient safety and effective cholesterol management.
Area of Science:
- Pharmacology
- Clinical Pharmacy
Background:
- Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors are widely prescribed for cholesterol management.
- These drugs, including lovastatin, simvastatin, pravastatin, and fluvastatin, possess varying pharmacokinetic profiles influencing their interaction potential.
Purpose of the Study:
- To review drug-drug, drug-food, and drug-disease interactions associated with HMG-CoA reductase inhibitors.
- To highlight potential risks and clinical significance of these interactions.
Main Methods:
- Literature review of interactions involving HMG-CoA reductase inhibitors.
- Analysis of pharmacokinetic differences and their impact on interactions.
Main Results:
- Significant interactions with cyclosporine, erythromycin, high-dose niacin, or gemfibrozil can lead to myopathy or rhabdomyolysis.
- Interactions with bile acid sequestrants, anticoagulants, and cardiovascular drugs generally have minor clinical significance.
- Food can affect the pharmacokinetics of lovastatin, pravastatin, and fluvastatin.
- Hepatic dysfunction necessitates contraindication; severe renal insufficiency may require dosage adjustments for lovastatin.
Conclusions:
- HMG-CoA reductase inhibitors, despite rare severe adverse effects, can interact dangerously with other substances and conditions.
- Awareness of these interactions is vital for safe and effective therapeutic use.